Supplementary Materials

Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment

Fabio Piscaglia, Sadahisa Ogasawara

Supplemental Table 1. An overview of trials comparing TACE with control (conservative management or suboptimal therapies) in hepatocellular carcinoma, updated with permission from Lencioni et al [11] copyright © 2012 Karger Publishers, Basel, Switzerland.

| Reference | Design | Treatment | Patients, n | Key inclusion criteria | Survival (%) | p value |
|-----------|--------|-----------|-------------|------------------------|--------------|---------|
| Pelletier et al. 1990 | RCT | TACE Conservative management | 21 | Cirrhosis; Okuda stage I–III | 24 21 | 31 | --- --- NS |
| GETCH 1995 [13] | RCT | TACE Conservative management | 50 | Cirrhosis; Child–Pugh A; Okuda I–II | 62 46 | 44 26 | 38 --- NS |
| Pelletier et al. 1998 | RCT | TACE Suboptimal therapy | 37 | Cirrhosis; Child–Pugh A and B; Okuda I–II | 51 36 | 55 26 | 24 --- NS |
| Lo et al. 2002 [15] | RCT | TACE Conservative management | 40 | Hepatitis B; Okuda I–II | 57 39 | 32 11 3 | 31 26 0.002 |
| Llovet et al. 2002 | RCT | TACE Conservative management | 40 | Hepatitis C; Child–Pugh A and B; | 82 35 | 63 27 17 | 63 29 0.009 |
| Study             | Design     | Treatment | Number | Disease Stage/Comorbidities | 5-Year OS | 5-Year RFS | p-Value  |
|-------------------|------------|-----------|--------|-----------------------------|-----------|-----------|----------|
| Luo et al. 2011   | Prospective| TACE      | 84     | Hepatitis B; portal vein tumor thrombosis | 30.9      | 9.2       | <0.001   |
|                   |            | Conservative management | 80     | B; portal vein tumor thrombosis | 3.8       | 0         |          |
| Dai et al. 2014   | Retrospective| TACE      | 131    | Hepatitis B; Child–Pugh A and B; BCLC stages B and C | 18.5      | 2.3       | <0.001   |
|                   |            | Conservative management | 156    | C; Child–Pugh A and B; BCLC stages B and C | 12.1      | 0         |          |
| Song et al. 2015  | Retrospective| TACE      | 119    | Hepatitis B; UICC III–IV A; portal vein thrombosis | 43.0      | 23.5      | <0.001   |
|                   |            | Conservative management | 27     | B; UICC III–IV A; portal vein thrombosis | 3.7       | 0         |          |

BCLC=Barcelona Clinic Liver Cancer; NS=not significant; RCT=randomized controlled trial; TACE=transarterial chemoembolization; UICC=Union for International Cancer Control.